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Background: Peritoneal carcinomatosis occurs in different cancer subtypes and is associated with a dismal
prognosis. Some doubts remain whether the whole abdomen can be treated by regional hyperthermia, therefore
we analyzed feasibility conducting a pilot study.
Methods: A simulation of the abdominopelvic heat distribution in 11 patients with peritoneal carcinomatosis was
done using the HyperPlan software and the SIGMA-60 and SIGMA-Eye applicators. Tissue-specific region-related
electrical and thermal parameters were used to solve the Maxwell’s equations and the bioheat-transfer equation.
Three-dimensional specific absorption rate (SAR) distributions and, additionally, estimated region-related perfusion
rates were used to solve the bioheat-transfer equation. The predicted SAR and temperature distributions were
compared with minimally invasive measurements in pelvic reference points.
Results: In 11 patients (7 of them treated in the SIGMA-60 and 4 in the SIGMA-Eye applicator) the measured
treatment variables (SAR, temperatures in the pelvic reference points) indicated that the heated volumes were
higher for the SIGMA-Eye applicator. The mean computed abdominal SARs were less for the SIGMA-Eye (33 versus
44 W/kg). Nevertheless, the temperature distributions in the abdomen (peritoneal cavity) were more homogeneous
in the SIGMA-Eye applicator as compared to the SIGMA-60 as indicated by higher values of T90 (mean 40.2 versus
38.2 °C) and T50 (mean 41.1 versus 40.2 °C), while the maximum temperatures were similar (in the range 41 to 43 °C).
Even though the mean abdominal SAR was lower in the SIGMA-Eye, the heat distribution covered a larger volume of
the abdomen (in particular the upper abdomen).
For the SIGMA-60 applicator the achieved T90 appeared to be limited between 41 and 42 °C, for the SIGMA Eye
applicator more effective T90 in the range 42 to 43 °C were obtained.
Conclusion: Our results suggest that an adequate heating of the abdomen and therefore abdominal regional
hyperthermia in PC patients appears feasible. The SIGMA-Eye applicator appears to be superior compared to the
SIGMA-60 applicator for abdominal hyperthermia.
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Table 1 Electrical parameters for computation of the power
deposition patterns and perfusion parameters (90 MHz)
Tissue Ɛr σ(S/m) Perfusion under RHT (ml/100g/min)
Muscle 80 0.8 30
Fat 10 0.04 20
Abdomen 36 0.55 20
Liver 78 0.6 100
Kidneys 83 1 400
Rectum 60 0.7 5
Perirectal tissue 23 0.3 20
Vagina 80 0.8 5
Bladder 80 0.6 5
Ɛr relative permittivity, σ(S/m) conductivity
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Peritoneal carcinomatosis (PC) occurs in different cancer
subtypes and is associated with a dismal prognosis. In
non-gynecologic malignancies such as colorectal, gastric,
pancreatic cancer as well as in peritoneal mesothelioma,
pseudomyxoma peritonei and primary peritoneal carcin-
oma a median overall survival (OS) of 3,1 months was
reported [1, 2].
On the other hand, ovarian cancer is the most frequently
type of gynecologic cancer accompanied by PC. In a single
center analysis of 214 patients with primary ovarian cancer
the initial surgery detected a peritoneal manifestation in
76 % [3]. The 5 year OS in advanced stage ovarian cancer
(Stage III/IV) is approximately only 25 % [4].
During the last decades several efforts have been made
to improve the therapy of PC. Besides intravenous
chemotherapy and cytoreductive surgery (CRS), the in-
traperitoneal chemotherapy and lastly CRS followed by
hyperthermic intraperitoneal chemotherapy (HIPEC)
were implemented. CRS and HIPEC were claimed to be
beneficial for patients with pseudomyxoma peritonei,
peritoneal mesothelioma and colorectal cancer [5, 6].
Less is known regarding the role of CRS and HIPEC for
PC in gastric cancer and for ovarian cancer [7–11]. As a
general limitation CRS is associated with notable morbid-
ity, mortality and a restriction of suitable patients [7–11].
Therefore abdominal regional hyperthermia (RHT) com-
bined with intravenous chemotherapy appears to be an
important non-invasive and well tolerated option in the
treatment of PC [12]. In two phase I/II studies at our cen-
ter we demonstrated that this approach was associated
with encouraging OS rates and low RHT associated toxic-
ities in patients suffering from PC of colorectal and ovar-
ian cancers [13, 14]. However, the beneficial effect of RHT
for the treatment of PC has never been demonstrated in a
randomized trial. Additionally, there were some doubts
whether RHT, using commercially available applicators
(such as the SIGMA-60 and SIGMA-Eye), could actually
lead to an appropriate heat distribution covering the
whole abdomen (including the peritoneal cavity). To facili-
tate the future use of RHT for the treatment of PC as well
as the need for innovative randomized trials incorporating
RHT we performed a planning study to evaluate whether
RHT of the abdomen using SIGMA-applicators is feasible.
Methods
We generated patient models for a group of 11 treated pa-
tients with PC. These 11 patients suffered from PC origin-
ating from different cancer subtypes and were randomly
selected from a larger cohort which underwent RHT in
the SIGMA-60 applicator or SIGMA-Eye applicator
within a phase I/II trial, as previously reported [13, 14].
On computed tomography (CT) scans we segmented the
target volume (abdominal cavitiy) and surrounding organsand structures like liver, kidneys, bones, muscles, fatty tis-
sue, vagina and bladder. Than specific patient models with
individual tetrahedron grids were generated and the finite
elements method (FEM) was used for the model calcula-
tions. The specific absorption rate (SAR)-distributions
(W/kg) were calculated using the treatment planning sys-
tem HyperPlan as previously described [15, 16]. For the
simulations we used assumed electrical, thermal and
physiological parameters of the tissues according to the
values previously reported. See [17–19] and Table 1. The
parameters for permittivity and conductivity showed no
relevant frequence dependend variety in our measurement
(70-100 MHz) and so the value for 90 MHz was used.
These parameters in conjunction with predicted SAR dis-
tributions were used to solve the bioheat-transfer equa-
tion. Applicator models for the SIGMA-60 applicator (8
dipole antennas arranged in pairs and connected to 4
amplifier channels) and SIGMA-Eye applicator (24 dipole
antennas arranged in pairs and connected to 12 amplifier
channels) were available. The hyperthermia planning sys-
tem HyperPlan has been tested and validated for both ap-
plicator models [15, 16].
The SAR and temperature distributions predicted via
HyperPlan can be compared with measurements in single
pelvic reference points in the rectum, vagina and bladder
(marked with star symbols in Fig. 1) by using the point
probe software tool of HyperPlan, which enables a meas-
urement of SAR or temperature of every specified point.
The measurement of SAR was performed using the
temperature decline in the time-temperature curve after
turning of the power after treatment.
Perfusion and its regulation during heat exposure is a
crucial characteristic of the tissues in order to compute
the temperature distribution. Liver and kidneys are the
highest perfused organs. The perfusion of the abdomen
was estimated as 20 ml/100g/min by assuming a mixture
of the intestine (basal perfusion of 40-50 ml/100g/min)
















Fig. 1 Arrangement of the annular-phased-array applicator, centered on the navel, for abdominal heating and centered 3 cm above symphysis
for pelvic heating. Sometimes the applicator position for SIGMA-60 differed from central plane as shown in Table 2. The reference points in
endoluminal catheters are also depicted (marked with colored stars)
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fusion during digestion (up to 6 fold) and has also (as
other organs) a self-protection ability against temperature
elevation. However, the thermoregulation in the visceral
organs is less pronounced than in other tissues (e.g. skin)
because the temperature in the portal vein might be as
high as 40 °C under physiological conditions (caused by
chemical processes during digestion). Therefore, a higher
tolerance against temperature increase might be assumed
in visceral organs. Furthermore, the intestinal perfusion
might even be depressed under somatic stress such as re-
gional hyperthermia. Therefore, 20 ml/100g/min is a rea-
sonable approach to describe the peritoneal cavity [19].
The maximum temperature in the organs such as intes-
tine, rectum and bladder was set to 43 °C. The perfusion
in other normal tissues such as muscle, fat or perirectal
tissue is under hyperthermic conditions higher than the
basal perfusion (Table 1).
In a first step, we reviewed for every patient, whether
the measurements in the reference points (both SAR
and temperature) could be correctly reproduced by the
corresponding patient-specific plan (using HyperPlan).
The computations are based on the patient anatomy (as
basis for a patient model), the treatment variables (fre-
quency, total power, phase amplitudes) and the tissueparameters according to Table 1. We started with the
applicator position described in the treatment protocol,
but for matching the plan to the measured data a slight
variation of the positions of the applicator and the point
probes was admitted. Variations of the positions in rela-
tion to the navel central plane (Fig. 1) were listed in
Table 2. Due to patient discomfort in some cases it was
necessary to shift the SIGMA-60 applicator a few cm
distal the navel as listed in Table 2.
In a second step, we evaluated the SAR and temperature
distributions from HyperPlan in the abdomen. We
used the described individual patient models, which
were assumed as validated after successful matching in
the first step.
In a third step, we varied (in particular increased) the
total power in the available patient models to estimate
the limitations of abdominal heating (with ring applica-
tors) under favorable conditions. The total power was
restricted, if a temperature threshold in any tissue was
exceeded. Because the total power is increased in steps
of 100 W, such a maximum permissible temperature
might be slightly passed in the simulation studies and
the generated temperature plots. We assume a self-
protection of all healthy tissues by increasing the perfu-
sion, if we go only slightly beyond the threshold.
Table 2 Analysis of the SAR and temperature distribution in the abdomen
SIGMA-60 SAR 50 (abdomen)
(W/kg)
T 90 (°C) T 50 (°C) T max (°C) SIGMA-Eye SAR 50 (abdomen)
(W/kg)
T 90 (°C) T 50 (°C) T max (°C)
70 MHz, 700
W, −2 cm
45 38,3 40,1 41,8 100 MHz,
1500 W
35 40,7 41,6 43,0
90 MHz, 600
W, −3 cm
42 38,3 40,6 42,7 100 MHz,
1600 W
36 39,9 41 42
90 MHz, 500 W 42 38,1 39,5 41,2 100 MHz,
1500 W
20 39,1 39,8 41,2
90 MHz, 600 W 43 38,2 40,7 42,2 100 MHz,
1500 W
40 41 41,9 42,8
90 MHz, 500
W, −3 cm
52 39,1 41 43,7 Mean value 33 40,2 41,1 42,2
70 MHz, 500
W, −4 cm
32 38 39,5 41,3
90 MHz, 550 W 40 37,6 39,8 42,2
Mean value 42 38,2 40,2 42,2
The applicator position is centered on the central plane (navel) as shown in Fig. 1. Distal aberrations (in cm) of applicator position to central position (required for
a few patients treated with Sigma-60) are listed in the left column
SAR specific absorption rate
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regulations of the local Ethics Committee of the Charité
Universitätsmedizin Berlin.
Results
In 11 treated patients (7 of them in the SIGMA-60 and
4 in the SIGMA-Eye applicator) particular treatment
variables (SAR, temperatures in the reference points)
were determined. We selected a typical heating session
for every patient. The average values for total power ap-
plied, absolute SAR and steady-state temperatures in the
reference points for all patients on each applicator were
created: For the SIGMA-60 applicator 500-700W,
SAR(vagina) 22 W/kg, SAR(rectum) 16 W/kg, Tvagina
40,8 °C and Trectum 40,3 °C. For the SIGMA-Eye applica-
tor 1400-1600W, SAR(vagina) 11 W/kg, SAR(rectum)
2 W/kg, Tvagina 40 °C and Trectum 39,4 °C. In all treat-
ments the phase delays were 0 and amplitudes were
equally weighted. No pattern optimization was per-
formed, because we assumed that the balanced phase
and amplitude control is near the optimum for the pur-
pose of abdominal heating.
The measured values indicate that the heated volumes
are higher for the SIGMA-Eye applicator, which needs
therefore higher total power. Nevertheless, the mean
SAR and temperatures in the pelvis are lower in the
SIGMA Eye applicator in comparison to the SIGMA-60
applicator. However, the considerably higher total (amp-
lifier) power required at the 12 amplifiers of the
SIGMA-Eye is mainly due to a lower efficiency, which is
nearly half of the SIGMA 60´s efficiency. The lower effi-
ciency is caused by losses in the matching networks (of
short antennas) and feeding cables. Furthermore, this
SIGMA-Eye applicator was used in a hybrid systemwhere additional loss of efficiency is caused by specifics
of the electro-technical separation of MRI and applicator
[13]. All these attributes had been included into the ap-
plicator models used in HyperPlan. Note that the power
levels given in this study for the SIGMA-Eye applicator
are different from power levels in a SIGMA-Eye applica-
tor outside the MRI.
We compared the measured temperatures and SAR in
the reference points with the values in the correspond-
ing patient-specific plans and performed a matching of
all measurements simultaneously by adapting the appli-
cator and point probe positions (see Methods). We
found in all patients already a satisfactory agreement in
the first approximation, but typically further improve-
ment was possible by a straight forward search in an un-
ambiguous direction of the parameter space. Finally, we
achieved a fair correlation as depicted in Fig. 2 with a
correlation coefficient of r = 0.997 for SAR and r = 0.90
for temperatures, respectively.
After completion of matching procedure we computed
the SAR and the temperature distributions in the whole
volume (pelvis and abdomen), using the verified patient
models and the refined positions of the central plane
(longitudinal shift from the belly button or navel). We
achieved median SAR and index temperatures in these
11 patient models as summarized in Table 2.
We noted characteristic differences between both ap-
plicators according to Table 2. The mean SAR were less
for the SIGMA-Eye (33 versus 44 W/kg). This was
mainly due to the lower SAR in the pelvic region by
using the SIGMA-Eye (see also Table 2). Nevertheless,
the temperature distributions in the abdomen (periton-
eal cavity) were more homogeneous in the SIGMA-Eye
applicator, which was indicated by higher T90 (40.2
Fig. 2 Correlation of measured SAR in the reference points and calculated values in HyperPlan after a matching process (see left). Correlation of measured
and calculated temperatures in the same reference points under the same conditions (see right). r= 0.997 for SAR and r= 0.90 for temperatures
Fig. 3 Simulated characteristic lines in a SAR/temperature diagram for
both applicators and the available patient models by variation of total
power until a threshold temperature is exceeded. Classification in easy
(lines shifted to the left) - and difficult-to-heat (lines shifted to the right)
patients. As the curves were very similar for patients treated in the
Sigma-60 applicator we show only 3 curves for this applicator (the
remaining curves would lie in the interspace between the depicted
curves) to enhance the clarity of the figure
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on average), while the maximum temperatures were
similar (in the range 41 to 43 °C). Even though the mean
SAR was lower in the SIGMA-Eye, the distribution cov-
ered a larger volume of the abdomen (in particular the
upper abdomen). Therefore, the T90 for the SIGMA-Eye
were above 40 °C on average, which might be sufficient
for some sensitizing effect in conjunction with chemo-
therapy (and radiotherapy).
We proceeded with the simulation study by further in-
crease of total power starting from the actual matched
treatments with the SIGMA-60 or the SIGMA-Eye appli-
cator. The SAR50 and T90 in the peritoneum belonging to
a particular power level and applicator are determined
plotted in a two-dimensional coordinate system (Fig. 3).
The plotted points rearrange in characteristic lines corre-
sponding to certain patients and applicators.
The total power was always turned off after a critical
temperature was exceeded (43 °C in the organs). Under
these conditions we could differentiate between easy-to-
heat (lines shifted to the left) and difficult-to-heat patients
(lines shifted to the right). For the SIGMA-60 applicator
the achieved T90 appeared limited between 41 and 42 °C,
and only exceptionally T90 reached 43 °C. For the SIGMA
Eye applicator we had to apply higher total power levels
and obtained a more effective T90 in the range of 42 to
43 °C. Even for the most difficult-to-heat patient we finally
achieved a T90 of 42 °C without exceeding a temperature
threshold. Evidently, we could heat a higher volume of the
abdomen with more homogeneity and a better covering
by use of the SIGMA Eye applicator.
The different patterns are illustrated by Fig. 4, which
shows SAR and temperature distributions for both appli-
cators under comparable conditions for a selected model.
Both applicators were centered on the navel plane. TheSIGMA-60 applicator tended to heat the pelvis more ef-
fective. However, the SIGMA-Eye applicator covered the
upper abdomen better and gained after all a better T90 for
the whole abdomen.
The pattern of the SIGMA-Eye applicator may even be
improved by proper phase control. In our simulations
we could show the effect of a delay on the outer rings of
the applicator resulting in a broadening of the effective
heating volume and an increased SAR. A phase delay of
Fig. 4 Comparison of typical SAR and temperature patterns gained with the SIGMA-60 applicator (left) and the SIGMA-Eye applicator (right). In
the SIGMA-60 the pelvic region is more effectively heated, while the upper abdomen is better covered in the SIGMA-Eye applicator. The dorsal
temperature hotspot represents a local effect on the border of bone and fatty tissue with no consequence for nearby structures, particularly there
is no critical temperature enhancement in the bony shielded spinal canal
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proper phase control of SIGMA-Eye in comparison to
SIGMA-60 and the resulting effects in effective heating
volume are depicted in Figs. 5 and 6. Note that for the
larger volume an elevation of the total power is also ne-
cessary in order to ensure a superior temperature distri-
bution with higher T90.Discussion
Our simulation study based on clinical experience and
measurements suggests an appropriate abdominal heating
capability using the annular-phased-array technique. Fur-
thermore our results show the applicability of SIGMA-60Fig. 5 Comparison of the pattern of effective heated abdominal volume fo
broadened pattern enabled by proper phase control in SIGMA-Eye applicatas well as SIGMA-Eye with a small advantage of SIGMA-
Eye applicator in abdominal RHT.
CRS/HIPEC, with its notable treatment related toxicity
and mortality rates, are objective of several ongoing and
completed retrospective and prospective trials. As re-
ported in retrospective and phase I/II trials there appears
to be a benefit for patients with pseudomyxoma peritonei,
peritoneal mesothelioma and colorectal cancer with PC
[5, 6, 20, 21]. However, for other cancer types e.g. ovarian
cancer even less supportive data for CRS/HIPEC exist.
Notably, even in experienced centers CRS/HIPEC proce-
dures were associated with toxicity rates between 0 and
40 % and mortality rates of 0–10 % and only a limited
number of patients (after careful selection) are actuallyr SIGMA-60 applicator (frequencies of 90 MHz and 70 MHz) and the
or
Fig. 6 Changes of effective heated volume using SIGMA-Eye applicator with standard adjustment and under proper phase control with a delay
of 50° on the outer applicator rings
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cologic origin grade 3–4 toxicity rates range from 29 to
40 %, whereas in ovarian cancer PC patients in 0–32 %
grade 3–4 morbidity was reported. Moreover in gyneco-
logic patients grade 3–4 hematologic morbidity of 8–31 %
was observed due to application of the intraperitoneal
chemotherapy [7–11]. Therefore, it appears unlikely that
CRS/HIPEC will truly improve the therapeutic ratio for a
large number of patients suffering from PC and thus,
other preferably non-invasive and better tolerated ap-
proaches are needed to intensify the treatment of patients
with PC.
Experiences with whole body hyperthermia (WBH)
showed promising results in several Phase II studies treat-
ing colorectal, ovarian and other cancer subtypes. How-
ever, it is associated with a grade III/IV toxicity rate of
3.1 % in 1300 described treatments. Moreover, the rate of
deaths in the first 30 days after WBH plus chemotherapy
treatment was 0.8 %. Furthermore WBH requires general
anaesthesia or deep analgesic sedation and is therefore
also logistically demanding. Clinical experience shows that
WBH is limited to 3-6 sessions because of this burden.
Therefore, WBH is neither for a palliative nor for a main-
tenance approach suitable [22–24].
In contrast RHT has been demonstrated as effective and
is associated with a very low rate of treatment related tox-
icities [12–14]. But it is important to consider current
quality assurance guidelines for treatment planning and
application [25, 26]. Moreover, with few exceptions (pace
maker, severe cardiac disease, metal implants in the treat-
ment area, acute thrombosis), RHT has less strict inclu-
sion criteria and can potentially be applied to a larger
proportion of patients suffering from PC than CRS/
HIPEC and WBH with its limitations as described before.
So far no randomized trial was initiated to test the com-
bination of RHT and chemotherapy vs. chemotherapyalone. Our group is currently developing a randomized
phase II trial who will address this question in patients
with recurrent ovarian cancer.
There are several limitations to our study. A major prob-
lem are direct (invasive) temperature measurements in the
abdomen/peritoneum. However, there are substantial prac-
tical obstacles to perform invasive measurements in these
seriously sick patients. Invasive thermometry would require
a laparoscopic placement or at least a radiological interven-
tion. Both procedures ar associated with morbidity and dis-
comfort (and even risks of complications as bleeding or
infection). In particular, invasive thermometry is not suit-
able for routine use. On the other hand, we widely used
minimally invasive temperature measurements with endo-
luminal catheters in rectum, vagina and/or bladder. The re-
placement of invasive intra-tumoral measurements by
endoluminal reference measurements (Fig. 1) is a generally
applied method and has been extensively discussed else-
where [27, 28]. Here, we combined potent planning tools
matched to reference measurements in order to achieve
the information outlined in this paper. This might be an
acceptable strategy for a first elucidation of abdominal
heating. Abdominal heating has a wide spectrum of
oncological indications (pancreatic cancer, ovarian can-
cer, colorectal cancer, gastric cancer and peritoneal car-
cinomatosis of different kinds), probably more than in
case of pelvic heating. For a broad application of ab-
dominal heating in the future, better specific quality
parameters a strongly desirable. Noninvasive thermom-
etry (MRI-thermometry) is the method of choice to ob-
tain the information needed with low morbidity and
clearly has much better acceptance in comparison to
invasive and minimally invasive thermometry [29].
However until now, noninvasive MRI-thermometry in
the abdomen is still a great challenge. Inhomogeneities
and motion are great obstacles to implement noninvasive
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inal heating MRI-thermometry of the liver could be a
promising concept, because it appears feasible and would
provide the mean temperature of the target, i.e. abdomen.
Another point of criticism might be the assumption of 20
ml/100g/min for the abdominal perfusion which has been
estimated considering current physiologic knowledge and
in accordance with former studies [19]. In case of incor-
rect perfusion parameters the temperature distribution
would change. For example a higher perfusion rate would
lead to lower abdominal temperatures. Again, MRI-
thermometry will elucidate the behavior of abdominal per-
fusion under heating conditions, which is a complex and
not yet completely resolved physiological issue. Despite
these objections we believe that an appropriate abdominal
heat distribution can be achieved by RHT and further
studies with RHT in the future are warranted in patients
with PC.
Conclusion
Our results suggest an adequate heating of the abdomen
and therefore abdominal regional hyperthermia in PC
patients appears feasible. This may facilitate the use of
RHT in future multidisciplinary trials for the treatment
of PC. To ensure a qualitative regional abdominal hyper-
thermia the combination of a hyperthermia treatment
planning and non invasive MRI-thermometry should
further be developed to be a standard combination in fu-
ture treatments [25]. The SIGMA-Eye applicator appears
to be the optimal applicator for abdominal RHT.
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